On February 26, the Senate Finance Committee held a hearing entitled, Drug Pricing in America: A Prescription for Change, Part II. The witnesses consisted of leaders from seven pharmaceutical companies. The goal of the hearing was to explore ways to lower drug costs and to understand more about the pharmaceutical supply chain. Several questions posed focused on pay for delay, list prices, rebate, and R&D. A full summary of the hearing is available. Additional drug pricing hearings are expected in coming months.